Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to determine if high dose vitamin D3 reduces the incidence of
musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with
early stage breast cancer and low serum vitamin D levels.
Phase:
Phase 2
Details
Lead Sponsor:
Qamar Khan University of Kansas
Collaborators:
BTR Group Novartis Pharmaceuticals
Treatments:
Aromatase Inhibitors Cholecalciferol Ergocalciferols Letrozole Vitamin D Vitamins